APYX
Apyx Medical Corporation3.7200
-0.0700-1.85%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
152.63MP/E (TTM)
-Basic EPS (TTM)
-0.36Dividend Yield
0%Recent Filings
8-K
Record Q4 revenue, AYON surges
Apyx Medical smashed Q4 2025 records with $19.2M revenue, up 35% YoY, fueled by 38% Surgical Aesthetics growth to $16.7M and nearly 50% U.S. surge from AYON launch in September. Full-year revenue hit $52.8M, swinging to positive Q4 Adjusted EBITDA of $0.7M. Guides FY2026 revenue to $57.5M-$58.5M. Demand outpaces expectations.
10-K
FY2025 results
Apyx Medical posted FY2025 revenue of $52.8M, up 9.9% y/y, driven by 17.4% Surgical Aesthetics growth to $45.3M from AYON's September launch, though OEM fell 20.9%; operating loss narrowed to $6.4M from $18.8M via op-ex cuts below $40M. Q4 momentum built on cost savings post-2024 restructuring and China Renuvion entry, with cash at $31.7M funding $8M op cash use. Equity raises netted $9.1M late-year. Debt covenants met. Litigation over product claims lingers.
8-K
Q4 revenue up 34% on AYON
Apyx Medical reported preliminary Q4 2025 revenue of $19.0-19.2M, up 34% year-over-year, driven by Surgical Aesthetics surging 38% to $16.6-16.8M—including 51% U.S. growth post-AYON launch. Full-year revenue hit $52.7-52.9M, up 10%, despite OEM's 21% drop. AYON fueled momentum. Final results due March 2026.
8-K
Filed Certificate Amendment
Apyx Medical filed a Certificate of Amendment to its Delaware Certificate of Incorporation on December 8, 2025, removing Article EIGHTH entirely and replacing it with 'intentionally omitted.' Stockholders had approved this change at the August 7, 2025 annual meeting. Amendment details in Exhibit 3.1.
8-K
Apyx closes $9.4M stock offering
Apyx Medical closed a public offering of 2,762,431 common shares at $3.62 each on November 19, 2025, with Lucid Capital Markets, raising ~$9.4M gross after 6% discount. Proceeds target working capital, sales expansion, capex, acquisitions, and debt repayment. Underwriter holds 45-day option for 414,365 more shares. Dilution hits shareholders now.
AEMD
Aethlon Medical, Inc.
2.94-0.11
AERG
Applied Energetics, Inc.
1.94-0.01
AMIX
Autonomix Medical, Inc.
0.63-0.03
BDMD
Baird Medical Investment Holdin
1.37+0.02
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
NVNO
enVVeno Medical Corporation
0.32+0.01
OFIX
Orthofix Medical Inc.
15.55-0.16
VYCO
Vycor Medical, Inc.
0.16+0.00